Montara to develop LRRK2 inhibitor drug for Parkinson’s
The Michael J. Fox Foundation (MJFF) has awarded a $3.3 million research grant to Montara Therapeutics to develop a brain-selective therapy for Parkinson’s disease using the company’s Brainonly platform. As part of the project, Montara will design and develop an LRRK2 inhibitor drug candidate that can reach…